Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus chemotherapy for recurrent or advanced endometrial cancer
ChiCTR2100045340Phase 4Recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in endometrial cancer (EC), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoint: Objective response rate. Started Apr 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2100045340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045340.